newsfilter
← Latest News
Business Wire·

Acorda Therapeutics Reports Second Quarter 2022 Financial Results

INBRIJA® (levodopa inhalation powder) Q2 2022 U.S. net revenue of $7.4 million; 16% increase from Q2 2021; 100% increase over Q1 2022 Ex-U.S. INBRIJA Q2 additional revenue of $1.9 million AMPYRA® (dalfampridine) Q2 2022 net revenue of $18.2